Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl
Launched by NATIONAL INSTITUTE ON DRUG ABUSE (NIDA) · May 28, 2025
Trial Information
Current as of July 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new tool called the Opioid Timeline Follow-Back (OpiTLFB) that helps researchers understand how people use nonmedical opioids, which are opioids obtained outside of a healthcare setting, like from friends or dealers. The goal is to improve the way we track and understand opioid use, especially in the context of the increasing presence of fentanyl, a powerful synthetic opioid.
To participate in this study, you need to be at least 18 years old and have used nonmedical opioids in the past 30 days. If you join, you will visit a clinic in Baltimore for 1 to 4 hours, where you will fill out a calendar about your opioid use over the last month and share your experiences. You will also provide a urine sample, which is a common part of such studies. This research is important because it can help develop better tools for tracking opioid use and understanding the challenges people face.
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- To be eligible to participate in this study, an individual must meet the following criteria:
- • 1. Age 18 years or older
- • 2. Past 30-day use of an opioid obtained in a nonmedical context (i.e., not from a pharmacy or in a healthcare setting)
- • 3. Able to understand and communicate in written and spoken English.
- • Justification: Initial development of the OpiTLFB requires strong, unmediated communication between the study team and the participants. Further development and modification for non-English-speaking interviewees is best undertaken as a separate project when the OpiTLFB is ready for use.
- • 4. Ability of subject to understand and the willingness to sign a written informed consent document.
- EXCLUSION CRITERIA:
- • 1. Any medical, psychiatric, or social conditions that the investigators believe would make participation in this protocol not in the best interest of the participant.
About National Institute On Drug Abuse (Nida)
The National Institute on Drug Abuse (NIDA) is a leading federal agency within the U.S. Department of Health and Human Services, dedicated to advancing the understanding of drug abuse and addiction through rigorous scientific research. NIDA's mission encompasses the exploration of the biological, behavioral, and social aspects of substance use disorders, facilitating the development of effective prevention and treatment strategies. By funding and conducting innovative clinical trials, NIDA aims to translate research findings into practical solutions that improve public health and inform policy, ultimately contributing to the reduction of substance-related harm in communities across the nation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
David H Epstein, Ph.D.
Principal Investigator
National Institute on Drug Abuse (NIDA)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported